CD8A and neoplasm: The presence of high levels of CD8+ infiltration not only serves as a prognostic marker but also suggests potential responsiveness to immune checkpoint inhibitors, such as programmed death (PD)-1 inhibitors (pembrolizumab, nivolumab) and cyotoxic T lymphocyte associated protein (CTLA)-4 inhibitors (ipilimumab), which may further enhance anti-tumor immunity [44,45].